beta,beta-Dimethylcysteine en es it fr

beta,beta-Dimethylcysteine Brand names, beta,beta-Dimethylcysteine Analogs

beta,beta-Dimethylcysteine Brand Names Mixture

  • No information avaliable

beta,beta-Dimethylcysteine Chemical_Formula


beta,beta-Dimethylcysteine RX_link

beta,beta-Dimethylcysteine fda sheet

beta,beta-Dimethylcysteine FDA

beta,beta-Dimethylcysteine msds (material safety sheet)

beta,beta-Dimethylcysteine MSDS

beta,beta-Dimethylcysteine Synthesis Reference

No information avaliable

beta,beta-Dimethylcysteine Molecular Weight

149.212 g/mol

beta,beta-Dimethylcysteine Melting Point

198.5 oC

beta,beta-Dimethylcysteine H2O Solubility

1.11E+005 mg/L

beta,beta-Dimethylcysteine State


beta,beta-Dimethylcysteine LogP


beta,beta-Dimethylcysteine Dosage Forms

Capsule; Tablet

beta,beta-Dimethylcysteine Indication

For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis

beta,beta-Dimethylcysteine Pharmacology

Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. It works by reducing numbers of T-lymphocytes, inhibiting macrophage function, decreasing IL-1, decreasing rheumatoid factor, and preventing collagen from cross-linking. Its use in Wilson's disease, a rare genetic disorder of copper metabolism, relies on its binding to accumulated copper and elimination through urine.

beta,beta-Dimethylcysteine Absorption

rapidly but incompletely

beta,beta-Dimethylcysteine side effects and Toxicity

No information avaliable

beta,beta-Dimethylcysteine Patient Information

No information avaliable

beta,beta-Dimethylcysteine Organisms Affected

Humans and other mammals